Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.

Launched by HOSPICES CIVILS DE LYON · Apr 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying ways to better understand and detect leftover cancer after surgery in patients with peritoneal metastases from colorectal cancer. Colorectal cancer can spread to different parts of the body, including the peritoneum, which is the lining of the abdominal cavity. After surgery to remove tumors, doctors currently use a scoring system to assess how much cancer remains, but this method is subjective. The trial aims to explore new biological markers that could provide a more accurate way to evaluate residual cancer by examining certain substances in the blood. These markers include circulating tumor DNA and other related elements that may indicate the presence of cancer cells.

Eligible participants for the trial are adults over 18 years old who have been diagnosed with colorectal cancer that has spread to the peritoneum and are scheduled for surgery. They must also meet specific health criteria, such as not having other active cancers. During the trial, researchers will monitor how these markers change in the blood around the time of surgery to determine the best time to measure them and to understand how they relate to inflammation in the body. This research could lead to more effective ways to track cancer after surgery and improve patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Common criteria:
• • Male/female over 18 years of age.
• • Weight ≥ 55 kg at inclusion.
• • Signature of a free and informed consent form.
• * Specific criteria:
• Group 1:
• • Peritoneal metastases colorectal cancer histologically proven
• • Synchronous or metachronous peritoneal metastases.
• • Patients eligible for initial cytoreduction surgery.
• • Non mucinous tumor (mucinous cells contingent \<30%).
• Group 2:
• • Colorectal cancer
• Group 3:
• • Non-oncological chronic inflammatory diseases
• Group 4:
• • Non-oncological chronic inflammatory diseases : parietal repairs, elective sigmoidectomy for diverticulosis
• Group 5:
• • Abdominal sepsis conditions: peritonitis due to digestive perforation in non-oncological pathology, non-perforated appendicitis, cholecystitis.
• Non inclusion Criteria:
• • Patient with an active cancer (excluding colorectal cancer).
• • Person with a progressive autoimmune disease.